Is It Too Late To Reassess Ligand Pharmaceuticals (LGND) After A 115% One-Year Rally?

• If you are wondering whether Ligand Pharmaceuticals at US$248.24 still offers value after a strong run, the next sections will break down what the current share price may be implying.
• The stock has delivered returns of 5.9% over the last week, 12.6% over the last month, 30.6% year to date and 115.1% over the past year, which has put valuation firmly in focus for many investors.
• Recent coverage has highlighted Ligand Pharmaceuticals in the context of its business model of acquiring and managing royalty streams in the pharmaceutical sector, as well as its position within the wider US biotechnology space. This news flow has helped frame the stock as one that is closely tied to expectations around future product royalties and licensing activity.
• On Simply Wall St’s valuation framework, Ligand Pharmaceuticals scores 3 out of 6 on its undervaluation checks. The rest of this article will compare different valuation approaches and then finish with a broader way of thinking about what that score really means for you.

Ligand Pharmaceuticals delivered 115.1% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Approach 1: Ligand Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock might be worth today by projecting future cash flows and discounting them back to a present value. It is essentially asking what a stream of future cash in today’s dollars could be worth.

For Ligand Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows in $. The latest twelve month free cash flow is about $121.8 million. Analyst and extrapolated projections in the model indicate free cash flow of $146.1 million in 2026, rising to $287.7 million by 2030, with later years extended by Simply Wall St beyond the analyst horizon.

When all these projected cash flows are discounted back, the DCF model arrives at an estimated intrinsic value of about $377.63 per share. Compared with the current share price of $248.24, this implies the stock is 34.3% below that intrinsic estimate, which, within this framework, indicates the shares are trading at a discount to this cash flow based valuation.

Result: UNDERVALUED (according to this DCF model)

Our Discounted Cash Flow (DCF) analysis suggests Ligand Pharmaceuticals is undervalued by 34.3%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Ligand Pharmaceuticals.

Approach 2: Ligand Pharmaceuticals Price vs Earnings

For profitable companies, the P/E ratio is a useful way to link what you pay for the stock to the earnings it is currently generating. It gives you a quick sense of how many dollars investors are paying for each dollar of earnings.

What counts as a “normal” or “fair” P/E depends on how fast earnings are expected to grow and how risky those earnings are. Higher expected growth or lower perceived risk can justify a higher P/E, while lower growth or higher risk often lines up with a lower P/E.

Ligand Pharmaceuticals currently trades on a P/E of 32.40x, compared with an average of 15.22x for the Pharmaceuticals industry and a peer group average of 63.10x. Simply Wall St also calculates a proprietary “Fair Ratio” for Ligand Pharmaceuticals of 20.62x. This Fair Ratio is designed to be more tailored than simple peer or industry comparisons because it incorporates factors such as the company’s earnings growth profile, risks, profit margins, industry, and market capitalization.

Comparing the current P/E of 32.40x with the Fair Ratio of 20.62x suggests the stock is trading above this model based reference point.

Result: OVERVALUED

Wall Street’s queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab’s valuation page.

Upgrade Your Decision Making: Choose your Ligand Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you connect your view of Ligand Pharmaceuticals’ story to actual numbers by setting your own assumptions for future revenue, earnings, margins and fair value. You can then compare that fair value to the current price, with each Narrative updating automatically when fresh information like news or earnings arrives. This means two investors can reasonably see things very differently. For example, one might build a bullish Ligand Pharmaceuticals Narrative that lines up with the upper analyst fair value of about US$330 per share based on stronger royalty growth and margins. Another might anchor to the lower fair value of about US$247 per share if more cautious on royalty concentration and regulatory risks. Both of these story plus forecast combinations can sit side by side in the Community page so you can quickly see which version of the future you find more reasonable before deciding how to act.

Do you think there’s more to the story for Ligand Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com